Most Read Articles
01 Jun 2015
New drug applications approved by US FDA as of 15 – 31 May 2015 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
10 Oct 2016
Use of dipeptidyl peptidase-4 (DPP-4) inhibitors may reduce the risk of mortality and the combination of myocardial infarction and ischaemic stroke in type 2 diabetes (T2D), without increasing the risk of hospitalisation for heart failure even in T2D patients with pre-existing HF, a nationwide cohort study from Taiwan suggests.

Product Highlight - Invokana

16 Dec 2016
INVOKANA – Canagliflozin hemihydrate 100 mg and 300 mg FC tab – Johnson & Johnson (Janssen)
  • INVOKANA demonstrated statistically significant glycated haemoglobin A1c (HbA1c) reductions and helped more patients achieve the ADA-recommended HbA1c goal of <7%1,4.
  • Only Invokana 300 mg demonstrated greater reductions in vs HbA1c sitagliptin 100 mg2.
  • INVOKANA results in the excretion of approximately 77 grams to 119 grams of glucose per day3.
  • INVOKANA provided greater reductions in body weight and systolic blood pressure vs placebo3.
  • INVOKANA showed good tolerability profile with the following most common adverse reactions – female genital mycotic infection, urinary tract infection (UTI) and increased urination3.
References:
1. Stenlöf K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab.2013;15(4):372-382.
2. Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care. 2013;36:2508-2515.
3. Invokana_Approved Prescribing Information_Malaysia_EU SmPC vJan2016.
4: American Diabetes Association. Standards of medical care in diabetes—2016. Diabetes Care. 2016; 39(Supplement 1): S39-S46.

Further information is available in Section 11b, New In This Issue and mims.com
Full prescribing information is available upon request.

MKT-CAN-MY-0026Creation Date: October 2016

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
01 Jun 2015
New drug applications approved by US FDA as of 15 – 31 May 2015 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
10 Oct 2016
Use of dipeptidyl peptidase-4 (DPP-4) inhibitors may reduce the risk of mortality and the combination of myocardial infarction and ischaemic stroke in type 2 diabetes (T2D), without increasing the risk of hospitalisation for heart failure even in T2D patients with pre-existing HF, a nationwide cohort study from Taiwan suggests.